Differential expression analysis was performed with Expression Suite software and selected miRNAs candidates were validated in the validation study by V Ltome PCR with U6-LNA miRNA qPCR assays and analyzed with 2^-ΔΔCt method. KruisKali-Wallis test, Dunns post-test and linear regression were used for statistical analyses.

**Results:** In the discovery study we were able to measure 379 (50%) of the miRNAs represented in the array. We observed that 10 miRNAs (miRNA-Let-7a, miRNA-96, miRNA-381, miRNA-451a, miRNA-518d, miRNA-425-5p, miRNA-672, miRNA-190b, miRNA-708, and miRNA-1180) were selected as equal in the same level at AMI and RA patients but were significantly downregulated compared with controls. These 10 miRNAs were selected as potentially miRNAs associated with the increase risk of CVD in RA patients. Four of those miRNAs were expressed at very low level and were discarded for the validation study. In the validation study with 214 plaque samples (73% with RA patients, we observed that two of the six candidate miRNAs (miRNA-425-5p and miRNA-451a) were significantly associated with cIMT. Thus, adjusted multivariable linear regression analysis showed that miRNA-425-5p and miRNA-451a independently explained 1.4% of the cIMT variability. Furthermore, adjusted regression estimates of the effect of miRNA-425-5p and miRNA-451a on cIMT were β = 0.029mm; p = 0.007 and β = -0.035 mm; p = 0.039, respectively. No other miRNA candidate exhibited association with cIMT values. Furthermore, we observed that miRNA-451a was significantly correlated with ESR (r=0.23; p=0.0001), CRP (r=0.15; p=0.016) and fibrinogen (r=0.28; p=0.029), whereas miRNA-425-5p was significantly correlated with fibrinogen (r=0.31; p=0.003) and ESR (r=0.23; p=0.016). Furthermore, miRNA concentrations were not affected by any of the AR treatments. No association was observed between the presence of carotid plaque and the expression level of the miRNAs tested.

**Conclusion:** In the present study, we have identified miRNA-425-5p and miRNA-451 as potentially miRNAs involved in the CVD risk observed in RA patients.

**Acknowledgement:** The authors thank the patients and healthy controls for their participation in the study.


**REFERENCES:**


---

**FR10008 ADDRESSING THE DIAGNOSTIC GAP IN RHEUMATOID ARTHRITIS BY COMPLEMENTING THE SEROLOGY WITH GENETIC INFORMATION**

Isabel Gehring1, Leonid Padyukov2, Yutao Fu3, Sascha Swiniarski3, Maryam Poorafshar4, Günter Steiner5, Lars Klareskog2.

**Background:** Rheumatoid arthritis (RA) is caused by an interaction of inherited and environmental factors. The genetic component was revealed in different twin studies and the shared epitope was identified as main contributor. During several genome-wide association studies (GWAS) different genes have been highlighted as relevant for developing RA but so far, none of these have been used for a diagnostic approach to address the diagnostic gap for RA.

**Objectives:** The aim of this study was to identify genes within pathways relevant for developing RA and to combine these genetic risk factors with serologic data to improve the diagnosis of RA, especially in regards to CCP negative RA patients.

**Methods:** The cohort consists of 804 RA patients, 159 Disease controls and 495 Healthy individuals. Serology data were obtained using the EliA CCP IgG, EliA RF IgM and EliA RF IgA (Phadia AB, Uppsala, Sweden) tests. The genetic measurements were performed using next generation Sequencing technology AmpliSeq™ on the Ion GeneStudio™ instruments (Thermo Fisher Scientific, Carlsbad, USA). The combined dataset was analysed by machine learning focusing on multivariate supervised models and discrete models.

**Results:** The Disease Research Area database (Thermo Fisher Scientific, Carlsbad, USA) uses a proprietary algorithm to create connections between genes and a specific disease highlighting relevant genes and pathways using the available datasets from NCBI, DisGeNet, ClinVar and further databases. Based on this information we were able to identify genes and variants within relevant pathways for RA and designed a sequencing panel specific for diagnosis of RA. The results from the targeted sequencing approach and the serologic data of the patients were analysed by an algorithm resulting in an improved diagnosis.

**Conclusion:** In this study the combination of genetic and serology leads to an improved sensitivity of over 10% compared to CCP alone, with a comparable specificity. This increase in sensitivity results in the identification of >20% CCP-negative RA patients. Additionally, a genetic pattern was identified distinguishing between CCP-negative and CCP-positive RA patients.

**Disclosure of Interests:** The authors thank the patients and healthy controls for their participation in the study.


**REFERENCES:**


---

**FR10009 MOLECULAR PROFILING OF CIRCULATING B-LYMPHOCYTES REVEALS THE SUPERIOR PERFORMANCE OF METHYLMETHE COMPOUNDS FOR TRANSCRIPTOME DATA FOR DISCRIMINATING RHEUMATOID ARTHRITIS PATIENTS IN AN EARLY ARTHRITIS CLINIC: IMPLICATIONS FOR TRANSLATING “BIG DATA” INTO CLINICALLY USEFUL TOOLS**

Nalib Naanang1, Nishanthi Thalayasingam1, Nisha Naile2, Andrew Clar2, Amy Anderson1, Dennis Lendrem1, Louise Reynard3, Stephen Eyre2, Anne Barton4, John Isaacs4, Arthur Pratt4, 5Newcastle University, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom; 6Manchester University, Arthritis Research United Kingdom Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester, United Kingdom; 7Newcastle University, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom

**Background:** Defining optimal strategies for translating “big datasets” of transcriptome and methylome data from clinically valuable tools in RA will benefit from comparisons with potential confounders—in particular, the clinical phenomemal stage of RA, disease phase and cell substrate heterogeneity—are controlled as far as possible.

**Objectives:** We have obtained paired B- and CD4+ T-lymphocyte whole genome expression and methylation data from drug-naive early arthritis clinic patients at a single centre. Focusing on B-lymphocytes data here we ask which of these datasets has most value in discriminating early RA and the additive value of combining them.

**Methods:** CD19+ B-lymphocytes were isolated by positive selection from fresh peripheral blood of 90 drug-naive patients attending the Newcastle Early Arthritis Clinic (NEAC), comprising 36 RA patients and 54 disease controls matched, so far as possible, for age, sex and acute phase response. Paired RNA and DNA extracted. Gene expression was profiled using the Human HT12 v4 BeadChip, and DNA methylation at >850,000 CpG sites quantified with the MethylxEPIC array (both Illumina). Gene expression and/or DNA methylation classifiers for RA prediction were developed based on a combined approach of classification algorithm